May 16, 2024
BURLINGTON, Ontario – May 16, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $250,000 in a fifth tranche of its previously announced private placement financing (the “Financing”), bringing the total amount raised to $1,960,000. ...
May 9, 2024
BURLINGTON, Ontario – May 8, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that further to its press release dated March 25, 2024, announcing a proposed equity private placement financing (the “Financing”), the Company has received an extension from...
April 16, 2024
BURLINGTON, Ontario – April 15, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $300,000 in a fourth tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...
April 3, 2024
BURLINGTON, Ontario – April 3, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $110,000 in a third tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...
April 1, 2024
BURLINGTON, Ontario – April , 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announced today that as contemplated in the secured convertible notes (the “Notes”) previously issued on its private placement financing (the “Financing”), the Company intends to issue common shares...
March 25, 2024
BURLINGTON, Ontario – March 25, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it plans to complete an equity private placement financing (the “Financing”) for up to $6,000,000 of gross proceeds, consisting of up to 35,294,117 common shares...
February 29, 2024
BURLINGTON, Ontario – February 28, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that effective February 28, 2024 (the “Effective Date”), the Company has cancelled an aggregate of 5,350,000 stock options (“Options”) to purchase common shares of the Company...
February 28, 2024
BURLINGTON, Ontario – February 23, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $200,000 in a second tranche of its previously announced equity private placement financing (the “Financing”), bringing the total amount raised to...
February 20, 2024
BURLINGTON, Ontario – February 16, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) today announced that it has closed on $1,100,000 in a first tranche of its previously announced equity private placement financing (the “Financing”) which contemplated up to $7,000,000 of...
February 8, 2024
Burlington, Ontario – February 7, 2024 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) trading on the Canadian Securities Exchange (“CSE”) under the symbol MKT:DOSE announces the appointment of Angela O’Leary to the Board of Directors. Mark Upsdell, CEO of RDT said ““We are...